By Susan Taylor (University of California, San Diego; HHMI)
Scientists have discovered a new drug that inhibits an overactive kinase implicated in cancer. How do the scientists determine the drug’s mechanism of action?
To help you prepare for this, answer the following sub-questions:
- What are the key structural components of a kinase?
- How do kinases regulate signaling pathways inside the cell?
- Why is it important for the cell to have an on/off switch?
Protein Phosphorylation in Biology
|Length: 23:07 minDownload: This Video|
|Trouble Viewing? Try it on iTunes.Report a problem.|
Architecture of a Protein Kinase
|Length: 28:15 minDownload: This Video|
In this lecture, I have given an overview of protein kinase structure and function using cyclic AMP dependent kinase (PKA) as a prototype for this enzyme superfamily. I have demonstrated what we have learned from the overall structural kinome which allows us to compare many protein kinases and also to appreciate how the highly regulated eukaryotic protein kinase has evolved. By comparing many protein kinase structures, we are beginning to elucidate general rules of architecture. In addition, I have attempted to illustrate how PKA is regulated by cAMP and how it is localized to specific macromolecular complexes through scaffold proteins.
Dr. Taylor received her BA in Chemistry from the University of Wisconsin-Madison and her PhD in Physiological Chemistry from Johns Hopkins University. After completing a fellowship at the MRC in Cambridge, she moved to the University of California, San Diego where she soon secured a faculty position in the chemistry department. Shortly after joining UCSD, Taylor began working on PKA and her lab has been investigating the mysteries of its structure and function ever since.
Dr. Taylor has been a Howard Hughes Medical Institute Investigator since 1997. She is a member of the National Academy of Sciences and the American Academy of Arts and Science and she has been awarded numerous prizes for her groundbreaking research.
- Susan Taylor iBioSeminar Part 3: Protein Kinase Regulation and Localization
- Brian Druker iBioSeminar: Imatinib as a Paradigm of Targeted Cancer Therapies